{
    "clinical_study": {
        "@rank": "18488", 
        "acronym": "EPIOSA", 
        "arm_group": [
            {
                "arm_group_label": "Obstructive slep apnea patients", 
                "description": "Patients with OSA"
            }, 
            {
                "arm_group_label": "Control group", 
                "description": "Subjects without OSA"
            }
        ], 
        "biospec_descr": {
            "textblock": "serum and plasma samples."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Changes in epigenetic regulation of genes involved in systemic inflammation and metabolic\n      dysfunction in OSA are linked with accelerated cardiovascular morbidity."
        }, 
        "brief_title": "Epigenetics Modifications in Obstructive Sleep Apnea", 
        "completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Sleep Apnea", 
            "Snoring"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Atherosclerosis", 
                "Sleep Apnea Syndromes", 
                "Snoring", 
                "Sleep Apnea, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Design. EPIOSA is a 5-yr non-interventional longitudinal prospective study being conducted\n      at the Sleep Clinic of the Hospital Miguel Servet, a large teaching hospital in Zaragoza\n      (Spain). Following a baseline visit, subjects are to be followed-up at 3 months, and then\n      every year.\n\n      Subject participation. The investigators will enroll a total 300 consecutive OSA male\n      patients aged 20-60 yrs, with baseline apnea-hypopnea index \u2265 5 events per hour of sleep\n      (AHI). In addition, 50 control subjects (AHI < 5) aged 20-60 yrs and matched by body mass\n      index (BMI) are also to be recruited. Exclusion criteria will include any comorbid condition\n      including alcohol and tobacco use.\n\n      Measurements: Routine clinical assessment, full sleep study, bilateral carotid\n      ultrasonography, biochemistry, circulating inflammatory cytokines, T cell subsets and\n      epigenetics studies at baseline and every year until at least 5 years of follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 18 to 60\n\n        Exclusion Criteria:\n\n          -  Any comorbid condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects that will be study because suspected OSA"
            }
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131610", 
            "org_study_id": "NCT01475421", 
            "secondary_id": "PI12/02175"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sleep apnea", 
            "Obstructive sleep apnea", 
            "Subclinical atherosclerosis", 
            "Epigenetics", 
            "T cells"
        ], 
        "lastchanged_date": "May 4, 2014", 
        "location": {
            "contact": {
                "email": "jmmarint@unizar.es", 
                "last_name": "Jose M Marin, M.D.", 
                "phone": "+34 976765500", 
                "phone_ext": "1941"
            }, 
            "facility": {
                "address": {
                    "city": "Zaragoza", 
                    "country": "Spain", 
                    "zip": "50009"
                }, 
                "name": "Hospital Miguel Servet"
            }, 
            "investigator": [
                {
                    "last_name": "Maria T Martin, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jose M Marin, M.D.", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "2", 
        "official_title": "Epigenetics Modifications and Subclinical Atherosclerosis in Obstructive Sleep Apnea: The EPIOSA Study", 
        "overall_contact": {
            "email": "jmmarint@unizar.es", 
            "last_name": "Jose M Marin, M.D.", 
            "phone": "+34976765500"
        }, 
        "overall_official": {
            "affiliation": "Hospital Universitario Miguel Servet", 
            "last_name": "Jose M Marin, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health and Consumption", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of cardiovascular events according with or without the presence of epigenetics changes in pro-inflammatory genes", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131610"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "biomarkers in blood and urine that correlates with OSA severity which may serve also as markers of disease progression.", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "Aragon Institute of Health Sciences", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Instituto Aragones de Ciencias de la Salud", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hospital Miguel Servet", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Aragon Institute of Health Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "April 2014"
    }
}